DOI: 10.2337/db06-1375 © 2007 by the American Diabetes Association Diet-Induced Increases in Adiposity, but Not Plasma Lipids, Promote Macrophage Infiltration Into White Adipose Tissue
1 Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee Address correspondence and reprint requests to Alyssa H. Hasty, Vanderbilt University Medical Center, Room 702 Light Hall, Nashville, TN 37232-0615. E-mail: alyssa.hasty{at}vanderbilt.edu
Abbreviations:
ATM, adipose tissue resident macrophage; LDLR, LDL receptor; MCP-1, monocyte chemoattractant protein-1; MIP-1
Obesity, hyperlipidemia, and insulin resistance are cardinal features of the metabolic syndrome and individually increase the risk for developing diabetes and cardiovascular disease, a risk that is amplified when they are simultaneously present. It is becoming increasingly clear that macrophages can infiltrate white adipose tissue (WAT) in the obese state, and their presence is associated with pathophysiological consequences of obesity, such as inflammation and insulin resistance. To determine whether hyperlipidemia could potentiate macrophage infiltration into WAT in the presence of obesity, obesity-prone agouti yellow mice (Ay/a) on a hyperlipidemia-prone LDL receptor (LDLR)–deficient (LDLR–/–) background were placed on chow or Western diet. In addition, Ay/a mice that were LDLR sufficient were also placed on Western diet. Both genetics and diet increased the degree of adiposity; however, plasma lipids were elevated only in the Western diet–fed LDLR–/– mice. The extent of macrophage accumulation in WAT correlated with the degree of adiposity. However, hyperlipidemia did not impact macrophage recruitment to WAT or the downstream metabolic consequences of macrophage accumulation in WAT, such as inflammation and insulin resistance. These data have important implications for the pathogenesis of diet-induced obesity in humans, even when plasma lipid abnormalities are not present. Obesity is a major health care concern because of its association with other pathological conditions related to the metabolic syndrome. Some of the risk factors associated with obesity include dyslipidemia, a pro-inflammatory state, hypertension, and insulin resistance (1,2). The dyslipidemia seen in obesity is characterized by elevated levels of nonesterified fatty acids (NEFAs), triglycerides, and small dense LDL particles, along with reduced levels of HDL (1–3). The individual components of the metabolic syndrome are independent risk factors for diabetes and cardiovascular disease; however, when these elements are concurrent, they have additive or even synergistic effects (2). In fact, individuals with familial combined hyperlipidemia are more insulin resistant compared with normolipidemic relatives, even after correcting for BMI (4). Moreover, insulin sensitivity is significantly lower in obese hyperlipidemic subjects compared with nonobese hyperlipidemic subjects (5). Therefore, the presence of both obesity and hyperlipidemia can exert an additive effect on insulin resistance.
Recent studies have explored various forms of obesity and found increased levels of macrophages in white adipose tissue (WAT) of obese rodents and humans compared with lean controls (6–13). In addition, multiple studies have established that adipose tissue resident macrophages (ATMs) are responsible for much of the inflammatory cytokine production in WAT in the obese state (8,10,14,15). Furthermore, it has been shown that macrophage infiltration into WAT precedes or is coincident with insulin resistance in obese mice (10). Weight loss has been shown to result in a decrease in ATM accumulation, and improved inflammatory status in humans, solidifying the association of obesity with macrophage infiltration of WAT (6,12,16). In addition, treatment of insulin-resistant humans with the insulin-sensitizing peroxisome proliferator–activated receptor Although research on macrophage infiltration into WAT is prominent at this time, the potential effects of other components of the metabolic syndrome, such as hyperlipidemia, on ATM content in the obese state remain to be elucidated. Fasting hypertriglyceridemia is often associated with increased visceral adiposity, linking hyperlipidemia with adiposity-related abnormalities (17,18). Plasma triglyceride levels are independently linked to inflammation and can be increased during acute infection or upon exposure to multiple inflammatory cytokines (19). In addition, pharmaceutical lowering of plasma lipid levels with statins has been shown to reduce plasma inflammatory cytokine levels (20). Finally, a recent report from Cancello et al. (7) demonstrated a strong positive correlation between ATM number and plasma triglyceride levels and a negative correlation with HDL cholesterol in obese humans. These observations led us to hypothesize that hyperlipidemia could also promote macrophage infiltration into WAT in the obese state and that a portion of the relationship between inflammation and hyperlipidemia could be attributed to increased ATM accumulation. To test this hypothesis, we used a series of mouse models with increasing obesity and hyperlipidemia to determine the contribution of hyperlipidemia to ATM accumulation. Analysis of these mice revealed that macrophage infiltration is correlated with the degree of adiposity; however, these effects were independent of the degree of hyperlipidemia. These data indicate that hyperlipidemia does not increase macrophage recruitment to WAT in obesity in this model system. In addition, our data highlight the fact that excessive dietary fat intake can promote adipose tissue dysfunction, leading to local and systemic inflammation as well as hyperinsulinemia and decreased adiponectin levels, irrespective of plasma lipid levels.
Mice and diets. The mice used in these studies were purchased from the Jackson Laboratories (Bar Harbor, ME) and are on a C57BL/6 background. Like wild-type mice, LDL receptor (LDLR)–/– mice are susceptible to diet-induced obesity and insulin resistance. In addition, they also develop hyperlipidemia (21,22), making them a useful model in which to study the physiological consequences of combined obesity and hyperlipidemia. The Ay/a;LDLR–/– mice were produced by intercrossing obesity-prone agouti yellow mice (Ay/a) with LDLR–/– mice. Mice were fed ad libitum and given free access to water. The Western diet was purchased from Harlan-Teklad (TD88137) and is set at a caloric density of 4.8 kcal/g with 42% of the calories from a fat source of anhydrous milk fat and 0.15% added cholesterol. All animal care and experimental procedures were performed with approval from and according to the regulations of the Institutional Animal Care and Usage Committee of Vanderbilt University.
Body composition.
Plasma collection and measurements.
Adiponectin measurement. Plasma samples were electrophoresed through nondenatured, nonreduced 4–12% SDS gels. Protein was transferred to nitrocellulose membranes and probed with rabbit anti-mouse adiponectin (ABCAM, Cambridge, MA) at a 1:2,000 dilution. Secondary antibody was used at a 1:5,000 dilution, and signal was detected using ECL reagents (Amersham, U.K.). Bands were quantified using the Quantity One software (Bio-Rad).
Adipose tissue histochemistry.
Gene expression.
Statistics.
Obesity, adiposity, and plasma lipids in chow diet–fed and Western diet–fed LDLR–/– mice. To determine whether hyperlipidemia contributes to macrophage infiltration into WAT in obesity, genetic and dietary manipulations were used. Obesity-prone mice, ubiquitously and ectopically expressing the agouti protein (Ay/a), were crossed with hyperlipidemia-prone LDLR-deficient (LDLR–/–) mice. At 4 months of age, male Ay/a;LDLR–/– mice and their control (a/a) littermates, a/a;LDLR–/–, were either maintained on chow diet or fed a high-fat, Western diet for 12 weeks. The resulting four experimental groups were as follows: 1) a/a;LDLR–/– mice on chow diet, 2) Ay/a;LDLR–/– mice on chow diet, 3) a/a;LDLR–/– mice on Western diet, and 4) Ay/a;LDLR–/– mice on Western diet. At the end of the diet feeding, body weight, total body fat, total plasma cholesterol, plasma triglycerides, and NEFAs were measured (Table 1). In every case, the Ay/a mice were heavier than their a/a controls, and the Western diet–fed mice were heavier than their chow diet–fed controls. This resulted in a stepwise increase in body weight going from the a/a;LDLR–/– chow diet mice to the Ay/a;LDLR–/– Western diet mice. The increase in weight gain was attributed to a gain in total body fat, a measure of adiposity, as determined by NMR analysis. After 12 weeks, total plasma cholesterol levels were dramatically increased in the LDLR–/– groups fed a Western diet, with the a/a;LDLR–/– Western diet and Ay/a;LDLR–/– Western diet groups displaying six- and eightfold increases compared with lean a/a;LDLR–/– chow diet mice, respectively (P < 0.001). Diet and genetics resulted in a synergistic increase in plasma triglyceride levels in the Ay/a;LDLR–/– Western diet group (1,059 ± 51 compared with 456 ± 36 mg/dl in the a/a;LDLR–/– Western diet group, P < 0.001). NEFA levels were also increased in the Western diet–fed a/a;LDLR–/– and Ay/a;LDLR–/– mice (P < 0.001). Thus, these four groups of mice provide a gradation of obesity and hyperlipidemia.
Adipose tissue morphology in lean, moderately obese, and severely obese mice.
Qualitative and quantitative analysis of macrophage markers in WAT. Based on the TBO images, it appeared that the Ay/a;LDLR–/– Western diet group had significantly greater ATM content than the other groups, suggesting that hyperlipidemia could increase macrophage infiltration into WAT. However, these mice were also more obese than the other groups. Thus, two additional groups were added: 1) a/a;LDLR+/+ mice fed Western diet; and 2) Ay/a;LDLR+/+ mice fed Western diet. Body weight and total body fat were slightly higher in the Western diet–fed LDLR+/+ groups compared with the Western diet–fed LDLR–/– groups; however, plasma lipid levels were not elevated by the Western diet feeding because of the presence of LDLRs (Table 2). After TBO staining of WAT from the initial four groups, more specific immunohistochemical characterization of abdominal WAT from all six groups was performed using an antibody to the macrophage surface marker F4/80 (Fig. 2A–L). Similar morphological differences and degree of macrophage infiltration were detected in the Ay/a;LDLR+/+ Western diet mice as was noted in the Ay/a;LDLR–/– Western diet (Fig. 2, compare F and L with E and K).
Abdominal WAT from all six groups was also collected for the evaluation of gene expression of macrophage markers F4/80 and CD68 using quantitative RT-PCR. Mirroring the stepwise increase in body weight and total body fat (Tables 1 and 2), there was an incremental increase in F4/80 and CD68 expression (Fig. 2M and N). Because of the slightly higher body weight and adiposity in the Western diet–fed LDLR+/+ mice compared with the LDLR–/– mice, subsets of mice were selected based on their total body fat mass so that there were no significant differences in the mean total body fat masses between each subset. The mean body fat mass of the moderately obese hyperlipidemic a/a;LDLR–/– Western diet group was matched to the normolipidemic a/a;LDLR+/+ Western diet group. Likewise, the mean body fat mass of the severely obese hyperlipidemic Ay/a;LDLR–/– Western diet group was matched to the normolipidemic Ay/a;LDLR+/+ Western diet group (Fig. 3A and B; a/a;LDLR–/– chow diet and Ay/a;LDLR–/– chow diet are included for reference). By controlling for adiposity, the specific contribution of hyperlipidemia to ATM accumulation in settings of moderate and severe obesity could be determined. Evaluation of F4/80 and CD68 expression in the adiposity-matched groups revealed that hyperlipidemia did not increase ATM accumulation in the LDLR–/– mice compared with their normolipidemic LDLR+/+ controls (Fig. 3C and D). In fact, F4/80 expression was elevated in the normolipidemic Ay/a;LDLR+/+ Western diet group compared with the hyperlipidemic Ay/a;LDLR–/– Western diet group (Fig. 3C).
Correlation of ATM content with plasma lipid levels. To further address our hypothesis that hyperlipidemia can potentiate macrophage accumulation in WAT in obesity, we performed correlative analyses using F4/80 and CD68 gene expression in relation to total plasma cholesterol, NEFA, and triglyceride levels for each of the six groups individually. Neither F4/80 nor CD68 expression correlated with total plasma cholesterol or NEFA levels in any of the groups (data not shown). There was a positive correlation between F4/80 expression (but not CD68) and plasma triglyceride levels only in the a/a;LDLR–/– Western diet group (F4/80, r2 = 0.24, P < 0.05; CD68, r2 = 0.16, P = 0.07). However, there was also an association between plasma triglycerides and body fat mass in this group (r2 = 0.24, P < 0.05). Taken together, these data do not support a role for hyperlipidemia aggravating ATM accumulation in obesity in this model.
Correlation of ATM accumulation with moderate and severe obesity.
Data from Fig. 2 demonstrate that severe obesity is associated with a greater degree of macrophage infiltration of WAT; however, these data do not indicate whether ATM content correlates with obesity in both moderate and severe conditions. Thus, we performed correlative analyses on the moderately obese a/a;LDLR–/– Western diet and a/a;LDLR+/+ Western diet groups combined and on the severely obese Ay/a;LDLR–/– Western diet and Ay/a;LDLR+/+ Western diet mice combined. Body weight was significantly correlated with WAT macrophage content in both moderately and severely obese mice. Surprisingly, the correlation between body weight and F4/80 expression was stronger in the moderately obese mice than in the severely obese mice, where more macrophages were detected (r2 = 0.53, P < 0.0001 and r2 = 0.24, P = 0.01, respectively; Fig. 4C). In addition, ATM numbers correlated with total body fat only in the moderately obese group (r2 = 0.55, P < 0.0001; Fig. 4D). These data suggest that adiposity contributes to macrophage accrual in moderate obesity, but other factors may play a more significant role in the continued recruitment of macrophages to WAT in severe obesity.
Effects of obesity and hyperlipidemia on inflammation in WAT.
Effects of obesity and hyperlipidemia on circulating levels of SAA, insulin, leptin, and adiponectin. In addition to examining the effects of obesity and hyperlipidemia on macrophages in WAT, we also sought to determine whether systemic abnormalities commonly linked with the metabolic syndrome, such as a pro-inflammatory state, insulin resistance, and leptin resistance (33–35), were impacted by the severe obesity seen in Ay/a;LDLR–/– Western diet and Ay/a;LDLR+/+ Western diet mice. To assess the degree of systemic inflammation in our mouse model, we measured circulating levels of SAA (Fig. 6A). SAA levels increased according to the extent of obesity, with a/a;LDLR–/– chow diet mice having the lowest level (1.4 ± 0.3 µg/ml); Ay/a;LDLR–/– chow diet, a/a;LDLR–/– Western diet, and a/a;LDLR+/+ Western diet groups showing two-, six-, and fivefold increases (2.7 ± 0.7, 7.9 ± 0.7, and 6.4 ± 0.8 µg/ml, respectively); and severely obese Ay/a;LDLR–/– Western diet and Ay/a;LDLR+/+ Western diet groups demonstrating 15- and 11-fold increases over lean mice (20.6 ± 1.9 and 15.6 ± 2.3 µg/ml, respectively, P < 0.01; Fig. 6A). Plasma insulin levels increased with obesity and mirrored the extent of macrophage infiltration into WAT (Fig. 6B). The coincidence of severe obesity with hyperlipidemia caused an increase in plasma leptin levels in the Ay/a;LDLR–/– Western diet group compared with the equally obese but normolipidemic Ay/a;LDLR+/+ Western diet group (122 ± 6 and 94 ± 5 ng/ml, respectively, P < 0.001; Fig. 6C). Plasma adiponectin levels were dramatically decreased by Western diet feeding and were lower in LDLR+/+ groups compared with LDLR–/– groups. Thus, the increased hyperinsulinemia and decreased adiponectin levels suggest a loss of insulin sensitivity in the more obese groups that display increased ATM accumulation.
Obesity is an integral part of the metabolic syndrome and is commonly associated with other metabolic disturbances such as dyslipidemia, inflammation, and insulin resistance. Although hyperlipidemia is not always present with obesity, the combination of the two has been shown to have an increased effect on the abnormalities linked with the metabolic syndrome (2,5). Much attention has been focused recently on the observation that macrophages infiltrate WAT in obesity; however, the impact of hyperlipidemia on this process has yet to be established. In our current study, we used a series of mouse models in which body weight and plasma lipid levels were manipulated such that the contribution of hyperlipidemia to ATM accumulation could be evaluated in both moderate and severe obesity. Contrary to expectations, hyperlipidemia did not increase macrophage infiltration into WAT in either moderate or severe obesity. In addition, our current data demonstrated the following novel findings: 1) ATM accrual correlated with adiposity in moderate but not severe obesity; yet 2) ATM numbers, as well as local and systemic inflammation, were disproportionately increased in severe obesity; and 3) dramatic morphological changes occurred in WAT from severe compared with moderately obese mice. There is some evidence in the literature suggesting that hyperlipidemia could contribute to ATM accumulation. Hyperlipidemia is intimately associated with obesity and the metabolic syndrome and may contribute to or be caused by inflammation (1,19). In fact, plasma triglyceride levels have been shown to positively correlate, and HDL inversely correlate, with ATMs in humans (7). Thus, it is reasonable to hypothesize that hyperlipidemia could also promote macrophage migration to WAT. Although our current study comparing moderately and severely obese mice with and without hyperlipidemia does not support this hypothesis, the scope of our findings is limited by the use of a single cause of hyperlipidemia, i.e., LDLR deficiency. We cannot rule out the possibility that the lack of LDLRs directly affects lipid deposition within WAT, with potential implications to the attraction of macrophages to WAT. In our studies, the a/a;LDLR–/– Western diet group did display a positive correlation between plasma triglycerides and ATM numbers similar to what was found in humans (7). However, in this group, plasma triglyceride levels were also correlated with total fat mass. Thus, in the studies by Cancello et al. (7), it is possible that positive and negative correlations of WAT macrophages with plasma triglyceride and HDL levels, respectively, were reflective of increased obesity (7). Therefore, plasma lipids may correlate with ATM numbers when their levels are causally affected by the increased adipose tissue. Finally, our studies were performed in mouse abdominal WAT, which may respond differently to hyperlipidemia than human visceral WAT. In this model system, severely obese mice clearly had more macrophages in their WAT than moderately obese mice, but the strong correlation between adiposity and ATM accumulation seen in moderate obesity was not present. These data suggest that there is no upper limit in the extent to which macrophages can accrue in WAT; however, the factors contributing to their accrual may differ depending on the degree of obesity. It is likely that early macrophage recruitment, seen in moderate obesity, is driven by the adipocytes, hence the strong correlation between ATM and obesity. In fact, unpublished data from our laboratory demonstrates that the adipokine leptin is a potent monocyte chemoattractant. In contrast, the exaggerated increase in ATMs in severely obese mice, relative to the increase in adiposity, suggests that macrophages themselves become the dictating factor in propagating the recruitment of additional macrophages.
We also observed that the pattern of local and systemic inflammation mirrored the extent of macrophage infiltration into WAT more closely than plasma lipid levels. Previous studies have shown that ATMs secrete the majority of inflammatory cytokines found in WAT (8,10,14,36). In our Western diet–fed Ay/a;LDLR–/– and Ay/a;LDLR+/+ animals, we detected dramatic increases in TNF- Macrophage accumulation in WAT is closely associated with insulin resistance and leads to the question of whether macrophage infiltration into WAT precedes insulin resistance or whether insulin resistance precedes ATM accumulation. Xu et al. (10) demonstrated that the presence of macrophages in WAT temporally preceded the development of hyperinsulinemia in mice. Conversely, Di Gregorio et al. (13) have shown that thiazolidinedione treatment of insulin resistance in humans results in reduced macrophage infiltration into WAT. Thus, macrophage accumulation in WAT may promote insulin resistance, and insulin resistance may then aggravate macrophage infiltration, creating a vicious cycle. The obese mice in our studies show a loss of protection against insulin resistance as evidenced by their decreased adiponectin levels (Fig. 6D). In addition, plasma insulin levels (Fig. 6B) increased in a fashion that mirrored ATM content (Fig. 2M and N). Together, these data provide support for the relationship between insulin resistance and macrophage infiltration into WAT. One very clear difference in WAT from the group with both severe obesity and elevated ATM content was a change in adipocyte morphology (Fig. 1). The WAT of these mice not only consisted of the hypertrophied adipocytes traditionally found in obesity, but also contained smaller adipocytes, creating a heterogeneous mixture of adipocyte sizes. These smaller adipocytes were always surrounded or crowned by macrophages. The explanation for size heterogeneity in these mice is not known. Cinti et al. (25) have suggested that macrophages are attracted to necrosing adipocytes to engulf the lipid core, resulting in what appears to be smaller adipocytes. Other studies have suggested that macrophages are attracted to adipocytes that are undergoing apoptosis (10). It has long been believed that hypertrophied adipocytes behave differently than normal-sized adipocytes. In support of this, a recent study from Jernas et al. (37) demonstrated a change in inflammatory status of large versus small adipocytes. In this context, our study raises the question of whether the homogeneity of adipocyte size is also important. We speculate that WAT consisting of a normal, homogeneous population of small adipocytes is able to function properly. In moderate obesity, when adipocytes have hypertrophied yet remain in a homogeneous population, WAT physiology is mildly impaired. However, in severe obesity, when both small and large adipocytes exist in a heterogeneous population, WAT becomes dysfunctional. The impact of dietary manipulations in this mouse model should not be overlooked. The fat source of the Western diet used in this study consists of 69% saturated fatty acids, 27% monounsaturated fatty acids, and 4% polyunsaturated fatty acids. Saturated fatty acids have been traditionally known to have deleterious effects on health, but more recently, they have been specifically implicated in activating TLR4, leading to the expression of inflammatory gene products (38,39). Not only can saturated fatty acids activate TLR4, but polyunsaturated fatty acids can impede the activation of TLR4 (39,40). Interestingly, the TLR4 expression was more closely related to high-fat diet feeding than adiposity (Fig. 5C). During the preparation of this manuscript, Flier and colleagues (41) demonstrated a key role for TLR4 to ATM accumulation in high-fat diet–fed mice. Thus, it is possible that TLR4 present on ATMs is activated by an increase in saturated fatty acid flux in the Western diet–fed mice. Collectively, our data suggest that hyperlipidemia does not contribute to obesity-driven ATM accumulation and its downstream pathophysiological consequences such as inflammation and insulin resistance. These data may have important implications to the pathogenesis of diet-induced obesity, even when plasma lipid abnormalities are not present.
A.H.H. has received a Junior Faculty Award from the American Diabetes Association (1-04-JF-20) and a Pilot and Feasibility Award from the Vanderbilt Digestive Diseases Research Center (VDDRC) (DK058404) and is also supported by a Scientist Development Grant from the American Heart Association (0330011N). Insulin and leptin assays were performed in the Analytical Services Core of the Diabetes Research and Training Center (DK20593)/Metabolic Pathophysiology Core of the Vanderbilt University Mouse Metabolic Phenotyping Center (DK59637). We received assistance from the Cell Imaging Core of the VDDRC for the immunohistochemical analyses (DK058404). We thank Drs. Richard OBrien and Larry Swift and members of our laboratory for their careful reading and critique of our manuscript.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received for publication September 28, 2006 and accepted in revised form December 2, 2006
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||